VARDENAFIL HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for vardenafil hydrochloride and what is the scope of patent protection?

Vardenafil hydrochloride is the generic ingredient in three branded drugs marketed by Bayer Hlthcare, Alembic, Macleods Pharms Ltd, Crossmedika Sa, Stevens J, Teva Pharms, and Zydus Pharms, and is included in ten NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Vardenafil hydrochloride has one hundred and seven patent family members in forty-three countries.

There are six drug master file entries for vardenafil hydrochloride. Eleven suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for VARDENAFIL HYDROCHLORIDE

International Patents:	107
US Patents:	2
Tradenames:	3
Applicants:	7
NDAs:	10
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	82
Patent Applications:	21
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VARDENAFIL HYDROCHLORIDE
What excipients (inactive ingredients) are in VARDENAFIL HYDROCHLORIDE?	VARDENAFIL HYDROCHLORIDE excipients list
DailyMed Link:	VARDENAFIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VARDENAFIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AriBio Co., Ltd.	Phase 3
Respira Therapeutics, Inc.	Phase 1
Johns Hopkins University	Phase 1/Phase 2

See all VARDENAFIL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for VARDENAFIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	10MG	TABLET, ORALLY DISINTEGRATING;ORAL
⤷ Sign Up	⤷ Sign Up	10MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for VARDENAFIL HYDROCHLORIDE

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VARDENAFIL HYDROCHLORIDE

G04BE	Drugs used in erectile dysfunction
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for VARDENAFIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STAXYN	Orally Disintegrating Tablets	vardenafil hydrochloride	10 mg	200179	1	2011-12-22
LEVITRA	Tablets	vardenafil hydrochloride	2.5 mg	021400	1	2009-09-04
LEVITRA	Tablets	vardenafil hydrochloride	5 mg and 10 mg	021400	1	2009-07-10
LEVITRA	Tablets	vardenafil hydrochloride	20 mg	021400	1	2009-03-05

US Patents and Regulatory Information for VARDENAFIL HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Crossmedika Sa	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	209057-003	Oct 31, 2018	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Macleods Pharms Ltd	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	204632-001	Oct 22, 2019	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva Pharms	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	091347-001	May 3, 2012	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alembic	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	214031-002	Aug 4, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva Pharms	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	091347-004	May 3, 2012	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for VARDENAFIL HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-003	Aug 19, 2003	⤷ Sign Up	⤷ Sign Up
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-004	Aug 19, 2003	⤷ Sign Up	⤷ Sign Up
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010	⤷ Sign Up	⤷ Sign Up
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-002	Aug 19, 2003	⤷ Sign Up	⤷ Sign Up
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-004	Aug 19, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for VARDENAFIL HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Africa	200707320	Pharmaceutical forms with improved pharmacokinetic properties	⤷ Sign Up
Costa Rica	20130381	FORMAS FARMACÉUTICAS CON PROPIEDADES FARMACOCINÉTICAS MEJORADAS	⤷ Sign Up
Cyprus	1112460		⤷ Sign Up
Croatia	P20131002	LIJEKOVI KOJI SADRŽAVAJU VARDENAFIL HIDROKLORID TRIHIDRAT (PHARMACEUTICAL COMPOSITIONS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE)	⤷ Sign Up
Israel	232538		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.